KISHORE GADDE, M.D.
Psychiatric at Erwin Rd, Durham, NC
License number
North Carolina 94-00058
Category
Psychiatric
Type
Psychiatry
Address
Address
2100 Erwin Rd, Durham, NC 27710
Phone
(919) 620-4467
Personal information
See more information about KISHORE GADDE at radaris.comName
Address
Phone
3 Winterfield Pl, Durham, NC 27705
101 Snow Crest Trl, Durham, NC 27707
3 Winterfield Pl, Durham, NC 27705
Organization information
See more information about KISHORE GADDE at bizstanding.comKishore Gadde MD
2301 Erwin Rd, Durham, NC 27710
Industry:
Psychiatrist
Phone:
(800) 266-3853 (Phone)
Kishore Murali Gadde
Professional information
See more information about KISHORE GADDE at trustoria.com
Dr. Kishore Gadde, Durham NC - MD (Doctor of Medicine)
Dr. Kishore Gadde, Durham NC - MD (Doctor of Medicine)
Specialties:
Psychiatry, Neuropsychiatry (Psychiatry)
Address:
Duke St S SUITE 3292, Durham 27710
2100 Erwin Rd, Durham 27705
2100 Erwin Rd, Durham 27705
(919) 620-4467 (Phone)
2100 Erwin Rd, Durham 27705
2100 Erwin Rd, Durham 27705
(919) 620-4467 (Phone)
Certifications:
Psychiatry, 1994
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Guntur Medical College, Ntr University Of Health Sciences
Graduated: 1978
Clinical Center At The Nih
University Hospital Of Cleveland
Western Mo Mntl Health Center
Guntur Medical College, Ntr University Of Health Sciences
Graduated: 1978
Clinical Center At The Nih
University Hospital Of Cleveland
Western Mo Mntl Health Center
Kishore M Gadde, Durham NC
Kishore M Gadde, Durham NC
Specialties:
Psychiatrist
Address:
2100 Erwin Rd, Durham, NC 27705
Board certifications:
American Board of Psychiatry and Neurology Certification in Psychiatry (Psychiatry and Neurology)
Method For Treating Obesity
Method For Treating Obesity
US Patent:
2006000, Jan 12, 2006
Filed:
Sep 7, 2005
Appl. No.:
11/222135
Inventors:
Kishore Gadde - Durham NC, US
K. Ranga Krishnan - Durham NC, US
K. Ranga Krishnan - Durham NC, US
International Classification:
A61K 31/36
US Classification:
514464000
Abstract:
The present invention relates, in general, to obesity, and, in particular, to a method of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight-loss promoting anticonvulsant either alone or in combination with bupropion or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.
Compositions For Affecting Weight Loss
Compositions For Affecting Weight Loss
US Patent:
2005027, Dec 15, 2005
Filed:
Apr 27, 2005
Appl. No.:
11/117139
Inventors:
Ranga Krishnan - Chapel Hill NC, US
Kishore Gadde - Durham NC, US
Kishore Gadde - Durham NC, US
International Classification:
A61K038/28, A61K031/7008, A61K031/4439, A61K031/426, A61K031/425, A61K031/19
US Classification:
514003000, 514243000, 514340000, 514369000, 514592000, 514635000, 514557000, 514023000, 514372000
Abstract:
Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an antidiabetic and the second compound is a anticonvulsant. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual with an antidiabetic and an anticonvulsant.
Method For Treating Obesity
Method For Treating Obesity
US Patent:
7425571, Sep 16, 2008
Filed:
Apr 23, 2004
Appl. No.:
10/830071
Inventors:
Kishore M. Gadde - Durham NC, US
K. Ranga R. Krishnan - Durham NC, US
K. Ranga R. Krishnan - Durham NC, US
Assignee:
Orexigen Therapeutics, Inc. - San Diego CA
International Classification:
A61K 31/42
US Classification:
514379
Abstract:
The present invention relates, in general, to obesity, and, in particular, to a method of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight-loss promoting anticonvulsant either alone or in combination with bupropion or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.
Compositions Of An Anticonvulsant And An Antipsychotic Drug And Methods Of Using The Same For Affecting Weight Loss
Compositions Of An Anticonvulsant And An Antipsychotic Drug And Methods Of Using The Same For Affecting Weight Loss
US Patent:
7429580, Sep 30, 2008
Filed:
Jan 11, 2005
Appl. No.:
11/034316
Inventors:
Kishore M. Gadde - Durham NC, US
K. Ranga R. Krishnan - Chapel Hill NC, US
K. Ranga R. Krishnan - Chapel Hill NC, US
Assignee:
Orexigen Therapeutics, Inc. - San Diego CA
Duke University - Durham NC
Duke University - Durham NC
International Classification:
A61K 31/553, A61K 31/55, A61K 31/497, A61K 31/42, A01N 43/00, A01N 43/62, A01N 43/80
US Classification:
514220, 51421113, 514218, 51425308, 51425406, 514379
Abstract:
Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is a psychotherapeutic agent and the second compound is a anticonvulsant. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual with a psychotherapeutic agent and an anticonvulsant.
Method For Treating Obesity
Method For Treating Obesity
US Patent:
2011009, Apr 28, 2011
Filed:
Jan 6, 2011
Appl. No.:
12/986043
Inventors:
Kishore M. Gadde - Durham NC, US
K. Ranga R. Krishnan - Chapel Hill NC, US
K. Ranga R. Krishnan - Chapel Hill NC, US
International Classification:
A61K 31/5375, A61P 3/04, A61P 9/12, A61K 31/423
US Classification:
5142308, 514379
Abstract:
The present invention relates generally to methods of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight loss-promoting anti-convulsant either alone or in combination with bupropion or metabolites thereof or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.
Compositions Of An Anticonvulsant And Mirtazapine To Prevent Weight Gain
Compositions Of An Anticonvulsant And Mirtazapine To Prevent Weight Gain
US Patent:
7713959, May 11, 2010
Filed:
Aug 31, 2005
Appl. No.:
11/216904
Inventors:
K. Ranga R. Krishnan - Chapel Hill NC, US
Kishore M. Gadde - Durham NC, US
Kishore M. Gadde - Durham NC, US
Assignee:
Duke University - Durham NC
International Classification:
A61K 9/14, A61K 31/55, A61K 31/44, A61K 31/42, A61K 31/40, A61K 31/335, A61K 31/19, C07D 223/14, A01N 43/00, A01N 43/46, A01N 43/42, A01N 43/80, A01N 43/36, A01N 43/32, A01N 47/10, A01N 37/00
US Classification:
51421402, 424489, 514217, 514288, 514379, 514424, 514452, 514483, 514557, 540576
Abstract:
Disclosed are pharmaceutical compositions comprising mirtazapine and an anticonvulsant drug. Also disclosed are methods of preventing weight gain associated with the administration of mirtazapine comprising identifying a patient to whom mirtazapine is to be administered and administering to said patient a pharmaceutical composition comprising mirtazapine and an anticonvulsant drug. Further disclosed are methods of increasing the efficacy of mirtazapine comprising identifying a patient to whom mirtazapine is to be administered and administering to said patient a pharmaceutical composition comprising mirtazapine and an anticonvulsant drug.
Compositions Of An Anticonvulsant And Mirtazapine To Prevent Weight Gain
Compositions Of An Anticonvulsant And Mirtazapine To Prevent Weight Gain
US Patent:
2010017, Jul 15, 2010
Filed:
Mar 26, 2010
Appl. No.:
12/732901
Inventors:
K. Ranga R. Krishnan - Chapel Hill NC, US
Kishore M. Gadde - Durham NC, US
Kishore M. Gadde - Durham NC, US
International Classification:
A61K 31/55, A61P 3/04
US Classification:
51421402
Abstract:
Disclosed are pharmaceutical compositions comprising mirtazapine and an anticonvulsant drug. Also disclosed are methods of preventing weight gain associated with the administration of mirtazapine comprising identifying a patient to whom mirtazapine is to be administered and administering to said patient a pharmaceutical composition comprising mirtazapine and an anticonvulsant drug. Further disclosed are methods of increasing the efficacy of mirtazapine comprising identifying a patient to whom mirtazapine is to be administered and administering to said patient a pharmaceutical composition comprising mirtazapine and an anticonvulsant drug.
Method For Treating Obesity
Method For Treating Obesity
US Patent:
7754748, Jul 13, 2010
Filed:
Sep 5, 2008
Appl. No.:
12/205769
Inventors:
Kishore M. Gadde - Durham NC, US
K. Ranga R. Krishnan - Chapel Hill NC, US
K. Ranga R. Krishnan - Chapel Hill NC, US
Assignee:
Duke University - Durham NC
International Classification:
A61K 31/42
US Classification:
514379
Abstract:
The present invention relates, in general, to obesity, and, in particular, to a method of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight-loss promoting anticonvulsant either alone or in combination with bupropion or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.